Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Chest Drainage Catheters - Market Insights, Competitive Landscape, and Market Forecast - 2032" has been added to ResearchAndMarkets.com's offering. The chest drainage catheters market is projected to expand at a CAGR of 4.78% from 2025 to 2032, driven by the rising global prevalence of chronic conditions such as cancer and cardiovascular diseases. This growth trajectory is accompanied by advancements in catheter technology and increased healthcare access, rein ...

Integer (ITGR -7.11%), a leading medical device contract manufacturer, released financial results for Q2 FY2025 on July 24, 2025. The headline news was GAAP revenue reaching $476 million, up 11.4% from Q2 2024 and beating analyst estimates by $11.63 million. Adjusted earnings per share (EPS) came in at $1.55, matching expectations and representing a 19.2% increase year over year. Management raised profit guidance for the rest of the year, reflecting ongoing robust performance, especially in its main Cardio ...

Core Viewpoint - Johnson & Johnson's MedTech segment, which constitutes approximately 36% of total revenues, is experiencing growth driven by newly acquired cardiovascular businesses and new product uptake, but faces challenges in the Asia Pacific region, particularly in China due to government procurement programs and competitive pressures [1][2][4]. Group 1: MedTech Segment Performance - The MedTech segment's growth in Q2 is attributed to the acquisition of Abiomed and Shockwave, alongside the continued uptake of new products [2]. - Sales in China are negatively impacted by the volume-based procurement (VBP) program and an anticorruption campaign, with no expected improvement in 2025 [2]. - Competitive pressures are affecting growth in specific MedTech areas, such as PFA ablation catheters in U.S. electrophysiology [3]. Group 2: Future Outlook - Sales are anticipated to be higher in the second half of 2025 compared to the first half as the business overcomes challenging first-quarter comparisons and new products gain traction [4]. - Tariff-related costs are expected to negatively impact profits in the MedTech segment [4]. Group 3: Competitive Landscape - J&J's MedTech unit faces significant competition from major players like Medtronic, Abbott, Stryker, and Boston Scientific, each specializing in various medical technologies [4][5]. Group 4: Financial Performance and Valuation - J&J's shares have outperformed the industry with a year-to-date increase of 9.7%, compared to a 0.6% rise in the industry [6]. - The company's shares are reasonably priced, trading at a price/earnings ratio of 14.43, lower than the industry average of 14.99 and below its five-year mean of 15.73 [8]. - The Zacks Consensus Estimate for 2025 earnings has increased slightly from $10.60 to $10.62 per share over the past 30 days [10].

Company Overview - Teleflex has completed the acquisition of the majority of BIOTRONIK SE & Co. KG's Vascular Intervention business for €760 million, significantly enhancing its interventional access product line and global presence in cath labs [1][8] - The acquired business includes a diverse portfolio of coronary and peripheral intervention products, which are expected to bolster Teleflex's innovation pipeline [4][5] Financial Impact - The acquisition is projected to add $0.10 to Teleflex's adjusted earnings per share (EPS) in the first year, with increasing contributions in subsequent years [10] - Teleflex anticipates that the acquired products will generate revenues of €177 million ($204 million) in the second half of 2025, with a constant currency revenue growth expectation of 6% or better from 2026 onward [9] Market Context - The vascular intervention medical devices market was valued at $5.1 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% through 2033, driven by the rising prevalence of cardiovascular diseases and advancements in technology [11] Recent Developments - Teleflex has announced findings from a multinational study demonstrating the effectiveness of Arrow Chlorhexidine-Impregnated Central Venous Catheters, showing a 70.5% reduction in the incidence of CLABSI [12]

Key Takeaways JNJ's MedTech sales rose 4.1% in Q1 2025, driven by new products and recent acquisitions. Headwinds in China from VBP and anticorruption efforts are expected to persist through 2025. Stronger second-half 2025 sales expected as comps ease and product momentum builds up across segments.Johnson & Johnson (JNJ) is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J’s medical devices segment, called MedTech, o ...

LeMaitre Vascular (LMAT) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Dorian LeBlanc - CFOGeorge LeMaitre - Chairman & CEOShaymus Contorno - Equity Research AssociateDavid Roberts - President & DirectorMichael Petusky - Managing DirectorRick Wise - Managing Director - Medical Technology & SuppliesDaniel Stauder - Director - Equity Research Conference Call Participants Michael Sarcone - AnalystFrank Takkinen - Senior Research AnalystJim Sidoti - AnalystBrett Fishbin - Vice President & ...

LeMaitre Vascular (LMAT) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Dorian LeBlanc - CFOGeorge LeMaitre - Chairman & CEOShaymus Contorno - Equity Research AssociateDavid Roberts - President & DirectorMichael Petusky - Managing DirectorRick Wise - Managing Director - Medical Technology & SuppliesDaniel Stauder - Director - Equity Research Conference Call Participants Michael Sarcone - AnalystFrank Takkinen - Senior Research AnalystJim Sidoti - AnalystBrett Fishbin - Vice President & ...

LeMaitre Vascular (LMAT) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Speaker0 Welcome to the Lomate Vascular First Quarter twenty twenty five Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. Dorian LeBlanc, Chief Financial Officer of Lemaitre Vascular. Please go ahead, sir. Speaker1 Thank you, operator. Good afternoon, and thank you for joining us on our Q1 twenty twenty five conference call. With me on today's call ...